Published in Law and Health Weekly, December 11th, 2004
PAION said it chose the Philips-exclusive software to assist in the determination of safety and effectiveness of Desmoteplase in the treatment of stroke patients.
According to PAION, the software displays summary maps, which make it possible to distinguish between still-viable and non-viable infarcted tissue. It also includes quantitative color maps of cerebral blood flow, cerebral blood volume, mean transit time and time-to-peak. These provide valuable clinical information for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.